Showing results (261-270 of 300) with videos related to
Sort By:
Pageof 30
Nature Medicine|May 22, 2024
Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trialXiangyu Gao, Ke Ji, Yongning Jia, et al.Nature Medicine|March 7, 2025
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trialKohei Shitara, Yelena Y Janjigian, Jaffer Ajani, et al.Journal of Gastroenterology and Hepatology|January 5, 2020
Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trialJianming Xu, Rui-Hua Xu, Shukui Qin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2023
Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649Markus Moehler, Hong Xiao, Steven I Blum, et al.Lancet Regional Health. Americas|April 17, 2025
Type 2 diabetes and cause-specific mortality in Mexico City: a Mendelian randomisation analysisFiona Bragg, Pablo Kuri-Morales, Eirini Trichia, et al.Ebiomedicine|January 13, 2024
Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ studyLin Yang, Wen Zhang, Nanfeng Fan, et al.The Lancet. Oncology|May 17, 2020
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 studyJing Huang, Jianming Xu, Yun Chen, et al.International Journal of Epidemiology|July 12, 2025
A Mendelian randomization study of the effect of body mass index on 52 causes of death among 125 000 Mexican adults with admixed ancestryLouisa Gnatiuc Friedrichs, Pablo Kuri-Morales, Eirini Trichia, et al.Cancer|September 28, 2023
Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomasShivaani Kummar, Lin Shen, David S Hong, et al.The Lancet. Oncology|January 21, 2023
Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort studyJingyuan Wang, Joanne Xiu, Alex Farrell, et al.Pageof 30